-

Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Report highlights progress toward environmental, social and governance objectives

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders providing detailed insight into the company’s CSR progress and environmental, social and governance (ESG) efforts.

“Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Reducing our impact on the environment, fostering an inclusive culture and being active members of our communities gives our more than 100,000 colleagues the opportunity to make a difference every day.”

Highlights from the company’s annual CSR report include:

Environment

  • Achieved 12% reduction in absolute Scope 1 and 2 emissions compared to 2018, putting the company ahead of schedule towards its 2030 target to reduce Scope 1 and 2 greenhouse gas emissions by 30%, even as it expanded global capacity in 2020 and 2021.
  • Committed to net-zero emissions across its value chain by 2050, aligning the company’s climate strategy and goals with the Paris Agreement, and expanding on its existing 2030 target.

Operations

  • Increased direct and indirect spending with small and traditionally underrepresented businesses from $1.3 billion to $2.0 billion. This is part of a Supplier Diversity Program designed to proactively promote more inclusive procurement practices that reflect the company’s customer base, employees and communities.
  • Continued mobilization of company resources to accelerate development, manufacturing and distribution of products critical to the global pandemic response, becoming one of the largest testing suppliers to global relief organizations for use in more than 100 low- and middle-income countries.

Communities

  • Reached more than 100,000 students and 6,600 educators through science, technology, engineering and math (STEM) programming across 21 countries.
  • Volunteered more than 105,000 hours worldwide through local Community Action Councils.

Colleagues

  • Advanced its diversity and inclusion strategy including demonstrated progress in improving representation within company leadership positions.

In reporting our CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks including the Global Reporting Initiative (GRI) Sustainability Reporting Standards, United Nations Sustainable Development Goals (SDGs), the Value Reporting Foundation’s SASB Standards and the Task Force on Climate-related Financial Disclosures (TCFD). The company makes additional topic-specific ESG data available through CDP, EcoVadis, and the voluntary disclosure of its annual EEO-1 information.

Learn more at www.thermofisher.com/csr

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faste...

Thermo Fisher Scientific to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in New York City. The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a Q&A session. The live webcast of the presentation can be accessed via the Investors section of our website, https://ir.thermofisher.com. A replay of the webc...

Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food...
Back to Newsroom